One-year Outcomes of ACURATE neo2 vs TAVR Devices

This document is a research report detailing the one-year outcomes of the ACURATE neo2 compared to approved transcatheter aortic valve replacement (TAVR) devices in patients with severe aortic stenosis. The ACURATE IDE trial involved a prospective, multicenter, randomized study with 1,500 patients who were symptomatic and indicated for TAVR. The primary endpoint was a composite of all-cause mortality, stroke, or rehospitalization at one year. The report outlines the trial design, including key inclusion and exclusion criteria for participants, and provides statistical methods used for analysis. It also presents baseline characteristics of the study population, procedural characteristics, and the results of the primary endpoint analysis using Bayesian methods. The findings indicate the performance metrics of the ACURATE neo2 valve system, including its unique design features aimed at improving patient outcomes. The document concludes with a summary of the trial's enrollment timeline and the clinical follow-up results.